Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
News|Videos|May 23, 2022
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Author(s)Grace Halsey
Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.
Advertisement
Diabetes technology - it's a jungle out there for clinicians who aren't familiar with the myriad devices and features or who have some experience with one particular system for a few patients but want to know more about others available and how they compare. Even for clinicians who have experience with a range of devices and types, an unbranded, unabiased tool for quick comparison would be helpful.
These are the "user groups" Stanford University's Korey Hood, PhD and team had in mind when they designed DiabetesWise Pro, a new one-stop diabetes device comparison tool launched in April. Hood spoke with PatientCare Online recently about the knowledge gaps and range of comfort levels he and his team identified among clinicians when it comes to recommending diabetes technology.
He describes the needs they found and the DiabetesWise Pro solution in this excerpt from our interview.
For more of Patient Care's conversation wtih Dr Hood, see:
Korey Hood, PhD, is a professor of pediatric endocrinology and of psychiatry and behavrioal sciences at Stanford Univesity, Stanford, CA. Hood also directs NIH- and foundation-funded clinical research focused on health and quality of life outcomes for persons living with diabetes. He has lived with type 1 diabetes since he was a young adult.
Advertisement
Related to this article
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
2
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5